Establishment and Effects Evaluation of Evaluation System for Rational Use of Anti-tumor Drugs in Our Hospital
10.6039/j.issn.1001-0408.2017.29.35
- VernacularTitle:我院抗肿瘤药物合理应用评价体系的建立及实施效果评价
- Author:
Dianyou ZHOU
1
;
Jinsheng JIA
Author Information
1. 山西晋城无烟煤矿业集团有限责任公司总医院药学部
- Keywords:
Anti-tumor drugs;
Rational drug use;
Evaluation index;
Clinical pharmacist;
Delphi method
- From:
China Pharmacy
2017;28(29):4157-4160
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To construct evaluation system for rational use of anti-tumor drugs and evaluate the effects. METH-ODS:Based on medical records of 1 927 malignant tumor patients in our hospital during Jan.-Oct. 2014,the study adopted Delphi method to determine the evaluation indexes. Referring to foreign and domestic authoritative guidelines,related literatures and drug package inserts,according to evidence-based pharmacy method,the evaluation system for rational use of anti-tumor drugs in our hospital was established from 6 aspects such as chemotherapy plan,drug dose,drug pretreatment,solvent selection,drug concen-tration,dosing frequency. The tumor patients receiving chemotherapy were selected from our hospital in May(pre-intervention group,98 cases)and Dec.(post-intervention group,87 cases)in 2015,the special comment was conducted by using above sys-tem. The utilization of anti-tumor drugs was compared between 2 groups before and after intervention. RESULTS:The unreason-able utilization rate of anti-tumor drugs was 62.2% in pre-intervention group and 29.9% in post-intervention group;the unreason-able rates of drug dose,drug pretreatment,drug concentration and chemotherapy plan decreased from 30.6%,21.4%,8.2%, 6.1% to 12.6%,6.9%,4.6%,2.3%,respectively,with statistical significance(P<0.05). Irrational solvent selection and dosing frequency had not been improved significantly,without statistical significance(P>0.05). CONCLUSIONS:The establishment of evaluation system for rational use of anti-tumor drugs can improve irrational use of anti-tumor drugs. It is certainly feasible and can provide reference for clinical pharmacists standardizing clinical use of anti-tumor drugs.
